Servier Canada
Oncaspar®
ONCASPAR logo; ONCASPAR pegaspargase injection.

Comparative product overview

Select parameters for ASPARLAS®, ONCASPAR®, and RYLAZE™

ONCASPAR®

pegaspargase1

Indication in ALL

PrONCASPAR® (pegaspargase) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with ALL

Half-life

  • 5.8 days IM injection4
  • 5.3 days IV infusion4

Half-life based on PK data after a single dose of ONCASPAR® 2500 U/m2

Recommended dose

For patients <21 years of age with:

  • BSA >0.6 m2: 2500 U (equivalent to 3.3 mL ONCASPAR®)/m² every 14 days
  • BSA <0.6 m2: 82.5 U (equivalent to 0.1 mL ONCASPAR®)/kg body weight every 14 days

For patients >21 years of age:

  • 2000 U (equivalent to 2.67 mL ONCASPAR®)/m2 body surface area every 14 days

Shelf life

Proposed shelf life of 8 months. Keep refrigerated prior to use at 2°C to 8°C. Do not freeze or shake. Store vials in the original package to protect from light. Discard any unused portion. Do not use beyond the expiration date printed on the carton or vial.

Data from separate Product Monographs and regulatory documents; comparative clinical significance has not been proven.

Consult the individual Product Monographs for complete dosing and administration information.

Dosing protocols for ASPARLAS®*, ONCASPAR®†, and RYLAZE™‡

Product

Week 1

ONCASPAR®1

or

ASPARLAS®3

RYLAZE™4

*The recommended dose of ASPARLAS® is 2500 U/m2 IV no more than every 21 days.
†The recommended dose of ONCASPAR® for patients with BSA >0.6 m2 and aged ≤21 years is 2500 U (equivalent to 3.3 mL ONCASPAR®)/m² body surface area IV or IM every 14 days.
‡The recommended dosage of RYLAZE™ is 25 mg/m2 on Monday and Wednesday and 50 mg/m2 IM on Friday, for a total of six doses to replace each planned dose of pegaspargase.

= intravenous infusion

= intramuscular

Data from separate Product Monographs; comparative clinical significance has not been proven.

See individual Product Monographs for complete dosing and administration information.

Learn more about Servier Canada’s treatment options in ALL

Learn more

Consult the ONCASPAR® Product Monograph

Learn more

Have you heard about ASPARLAS®?

ASPARLAS® (calaspargase pegol for injection) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL in pediatric and young adult patients age 1 to 21 years.

Learn more about ASPARLAS®

aBFM: augmented Berlin-Frankfurt-Münster; ALL: acute lymphoblastic leukemia; BSA: body surface area; CNS: central nervous system; CSF: cerebrospinal fluid; DFCI: Dana-Farber Cancer Institute; ELISA: enzyme-linked immunosorbent assay; IM: intramuscular; IV: intravenous; PD: pharmacodynamics; PK: pharmacokinetics; NCCN: National Comprehensive Cancer Network®; TDM: therapeutic drug monitoring.

* Clinical significance has not been established.

† Comparative clinical significance has not been established.

‡ Fictitious cases. May not be representative of all patients.

§ Native E. coli L-asparaginase is not available in Canada.

References: 

  1. ONCASPAR® Product Monograph. Servier Canada. August 20, 2024.
  2. ONCASPAR_CPID Redacted.
  3. ASPARLAS® Product Monograph. Servier Canada. March 8, 2024.
  4. RYLAZE™ Product Monograph. Jazz Pharmaceuticals Canada Inc.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/all.pdf. Accessed November 8, 2024.
  6. Vrooman LM et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: Results of DFCI 11-001. J Clin Oncol. 2021;39(31):3496–3505.
Back to top

Stay Connected with Servier Canada

Stay up to date on disease information, treatment options, our products, and patient support programs.

Sign Up